Search the Newsreel

Iovance stock surges as Amtagvi powers Q2 beat (IOVA:NASDAQ)

Iovance Biotherapeutics (IOVA) stock surged over 40% to a new 52-week high after reporting Q2 2026 earnings that significantly exceeded Wall Street expectations. The strong performance was attributed to its cancer therapy, Amtagvi. The company maintained its revenue outlook under review.

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates

IOVA Stock Grants Signal Aggressive Post-Amtagvi Expansion

Iovance Biotherapeutics Inc. (IOVA) has granted inducement stock options for 139,930 shares to 17 new non-executive hires, signaling an aggressive post-Amtagvi expansion. These grants, with a $4.66 strike price and a three-year vesting period, suggest management's confidence in long-term growth following the FDA approval …

Iovance Biotherapeutics stock hits 52-week high at $5.97 By Investing.com

Iovance Biotherapeutics (IOVA) stock reached a new 52-week high of $5.97, reflecting a 64.39% appreciation over the past year. The company, which specializes in cancer immunotherapies, currently trades at $6.21 with a market capitalization of $1.94 billion. This milestone follows better-than-expected Q2 2026 results, …

Iovance Biotherapeutics Stock Grants Signal Post-Amtagvi Expansion

Iovance Biotherapeutics (NASDAQ: IOVA) is experiencing a 31.57% stock increase driven by positive sentiment surrounding its Amtagvi trial progress and a new hiring wave. The company granted inducement stock options for 139,930 shares to 17 new non-executive hires, indicating a significant expansion post-FDA approval …

IOVANCE BIOTHERAPEUTICS ($IOVA) Releases Q2 2026 Earnings

Earnings Flash (IOVA) Iovance Biotherapeutics, Inc. Reports Q2 Revenue $99.3M, vs. FactSet Est of $87.8M

Iovance Biotherapeutics, Inc. (IOVA) announced strong Q2 revenue, reaching $99.3 million, significantly surpassing FactSet's estimated $87.8 million. This positive financial performance was released alongside other company updates, including recent regulatory approvals for its Amtagvi therapy in Australia and FDA clearance for a new clinical …

Iovance Biotherapeutics reports record Q2 revenue ~$99.3M, gross margin 56%

Iovance Biotherapeutics reported record second-quarter 2026 product revenue of $99.3 million with a 56% gross margin, driven by strong U.S. Amtagvi demand. The company is reviewing its full-year 2026 revenue guidance following these robust results and expects continued gross margin improvement. Key highlights include …

Iovance Biotherapeutics Reports Record Second Quarter 2026

Iovance Biotherapeutics reported record second-quarter 2026 revenue of $99.3 million, a 66% increase year-over-year, driven by strong U.S. Amtagvi demand. The company is reviewing its full-year 2026 revenue guidance of $350 million to $370 million and expects to provide an update in the third …

Iovance Biotherapeutics (NASDAQ: IOVA) posts Q2 2026 $99.3M revenue

Iovance Biotherapeutics: Q2 Earnings Snapshot

Iovance Biotherapeutics (IOVA) reported a Q2 loss of $47.3 million, or 11 cents per share, with revenue reaching $99.3 million. The biotechnology company anticipates full-year revenue to be between $350 million and $370 million. This financial update was generated using data from Zacks Investment …

Bioventus earnings beat, revenue fell short of estimates

Bioventus, Inc.: Bioventus Reports Second Quarter Financial Results

Bioventus Inc. reported strong second-quarter 2026 financial results, with reported revenue increasing 4% to $153.2 million and GAAP earnings per diluted share rising significantly to $0.47. The company reaffirmed its full-year 2026 guidance for revenue, Adjusted Diluted EPS, and cash from operations, and announced …

Earnings call transcript: Bioventus posts Q2 2026 EPS beat, shares slip premarket

Enterprise value to EBIT forward of Iovance Biotherapeutics Inc – FWB:2LB

This article displays the Enterprise Value to EBIT forward for Iovance Biotherapeutics Inc (FWB:2LB) on the Frankfurt Stock Exchange. It indicates that the market is closed with no trades. The content is presented as a financial overview for the company.

Bioventus Shareholder Notice

Faruqi & Faruqi, LLP is investigating potential claims against Bioventus Inc. (NASDAQ: BVS) and reminds investors of the March 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Bioventus's offering documents and public …

Bioventus (BVS) Q2 Earnings Meet Estimates

Bioventus Reports Second Quarter Financial Results

Bioventus Inc. reported strong second-quarter 2026 financial results, with reported revenue increasing 4% to $153.2 million and GAAP earnings per diluted share rising significantly to $0.47. The company reaffirmed its full-year 2026 guidance for revenue, Adjusted Diluted EPS, and cash from operations, and announced …

Bioventus (Nasdaq: BVS) posts Q2 profit surge and weighs strategic options

Bioventus Inc. (Nasdaq: BVS) reported a significant surge in Q2 2026 net income to $33.4 million, up from $7.5 million year-over-year, driven by strong net sales of $153.2 million and the removal of a deferred tax asset valuation allowance. The company reaffirmed its full-year …

Bioventus Q2 Earnings Call Highlights

Bioventus Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:BVS) 2026-08-05

Bioventus (NASDAQ:BVS) Releases FY 2026 Earnings Guidance

Bioventus (BVS) Earnings Date and Reports 2026 $BVS

Bioventus Starts Review After Unsolicited Acquisition Proposal

Bioventus Q2 Revenue Rises 4% as Strategic Review Begins

5 Growth Stocks That Pass Peter Lynch's Favorite Test

This article identifies five growth stocks that align with Peter Lynch's investment philosophy, combining valuation discipline with strong financial health and growth prospects. It explains a screening methodology using the P/E ratio, Piotroski F-score, and five-year earnings growth rate to find companies like National …

Bioventus Shareholder Action Reminder

Faruqi & Faruqi, LLP is investigating potential claims against Bioventus Inc. (NASDAQ: BVS) and reminds investors of the March 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Bioventus's initial public offering documents …

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

BioNTech SE Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer ("CEO"), who will take office by February …

Iovance Biotherapeutics (IOVA) Is Down 18.4% After Early Amtagvi Rollout Update - Has The Bull Case Changed?

Guido Oelkers to step down as CEO of Sobi in the beginning of 2027

STOCKHOLM, Aug. 3, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announces that Guido Oelkers has informed the Board of Directors that he has decided to step down as Chief Executive Officer of Sobi to take up another position outside Sobi. Guido …

Iovance Biotherapeutics (IOVA) Stock May Be Cheap As Sales Ramp Remains Key

Iovance Biotherapeutics (IOVA) stock is showing signs of being undervalued according to Simply Wall St's framework, despite a significant 5-year decline. The valuation hinges on the company's ability to generate reliable revenue from its therapies and control cash burn. While it scores well on …

Iovance Biotherapeutics (IOVA) Heads Into Earnings With Its T Cell Therapy Story And Valuation In Focus

Iovance Biotherapeutics (IOVA) is approaching its Q2 2026 earnings report on August 6, 2026, with investors focusing on its first FDA-approved T cell therapy for solid tumors. Despite recent share price pullbacks, the company shows strong short-term momentum and is considered significantly undervalued by …

Class Action Lawsuit Filed Against Iovance Biotherapeutics, Inc

A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) on behalf of investors who suffered losses due to alleged securities fraud between May 9, 2024, and May 8, 2025. The lawsuit claims that Iovance made misleading statements about its growth …

Iovance Biotherapeutics (IOVA) Stock Looks Cheap On Sales While Returns Stay Weak

Iovance Biotherapeutics (IOVA) stock appears undervalued based on its sales multiple, trading at 6.4x sales compared to the biotech industry average of 10.5x and a tailored fair P/S ratio of 7.1x. Despite a recent rebound, long-term investors still face significant losses over five years, …

IOVA Stock Slides As Biotech Traders Watch Key Support

Iovance Biotherapeutics Inc. (IOVA) stock has dropped significantly, trading down 14.07% due to concerns over its cancer therapy pipeline. While the company has substantial cash reserves and modest debt, it remains unprofitable with high R&D spending. Traders are closely monitoring the $4 support level, …

Bioventus Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against Bioventus Inc. (NASDAQ: BVS) and reminds investors of the March 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that Bioventus made materially false …